Lusine Hovhannisyan

Lusine Hovhannisyan

Auto-generated profile, based on publicly available information

Lusine Hovhannisyan

Department for BioMedical Research, University of Bern, Bern, Switzerland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
RERoberta Esposito
Roberta Esposito
ALAndrés Lanzós
Andrés Lanzós
TUTina Uroda
Tina Uroda
SRSunandini Ramnarayanan
Sunandini Ramnarayanan
IBIsabel Büchi
Isabel Büchi
Rory JohnsonRory Johnson
Rory Johnson
Long noncoding RNAs (lncRNAs) are linked to cancer via pathogenic changes in their expression levels. Yet, it remains unclear whether lncRNAs can also impact tumour cell fitness via function-altering somatic “driver” mutations. To search for such driver-lncRNAs, we here perform a genome-wide analysis of fitness-altering single nucleotide variants (SNVs) across a cohort of 2583 primary and 3527 metastatic tumours. The resulting 54 mutated and positively-selected lncRNAs are significantly enriched for previously-reported cancer genes and a range of clinical and genomic features. A number of these lncRNAs promote tumour cell proliferation when overexpressed in in vitro models. Our results also highlight a dense SNV hotspot in the widely-studied NEAT1 oncogene. To directly evaluate the functional significance of NEAT1 SNVs, we use in cellulo mutagenesis to introduce tumour-like mutations in the gene and observe a significant and reproducible increase in cell fitness, both in vitro and in a mouse model. Mechanistic studies reveal that SNVs remodel the NEAT1 ribonucleoprotein and boost subnuclear paraspeckles. In summary, this work demonstrates the utility of driver analysis for mapping cancer-promoting lncRNAs, and provides experimental evidence that somatic mutations can act through lncRNAs to enhance pathological cancer cell fitness.

21 September 2023 in Neurological Sciences
Verified
Journal Article
Open access
PDF file
LHL. Hovhannisyan
L. Hovhannisyan
SKSamson G. Khachatryan
Samson G. Khachatryan
AKA. Khamperyan
A. Khamperyan
SMSenik Matinyan
Senik Matinyan
Purpose: Stem cells have been extensively used during the last decade to improve clinical outcomes after stroke. The dramatic increase in trials in this field has led us to perform a systematic review and meta-analysis to understand the safety, effectiveness, and relative limitations of this type of intervention. Method: This review summarizes the current evidence pooled from PubMed (Medline), EMBASE, EBSCOhost, http://clinicaltrials.gov, Scopus (Elsevier), Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science (Science Citation Index Expanded) databases for the use of stem cell therapies in stroke patients without combinations with other treatment modalities. The National Institutes of Health Stroke, modified Rankin Scales, and Barthel Index scores after external stem cell administration have been evaluated on the 3rd, 6th, and 12th months after treatment. The random effect analysis was performed using the Review Manager 5.4.1. The characteristics of stem cell sources and their adverse effects have been discussed as well. Findings: Although reasonably safe, the effectiveness evidence fluctuated to a large extent due to the heterogeneity of the clinical trials and the absence of a systematic approach. The stem cell sources and the administration window were not strongly associated with clinical outcomes. Conclusion: Further studies should be conducted to understand the deep discrepancy between preclinical and clinical trials and to execute phase 3 clinical trials with robust control of study characteristics and outcomes.

8 November 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
LHLiana Hayrapetyan
Liana Hayrapetyan
SRSelina M. Roth
Selina M. Roth
AQAurélie Quintin
Aurélie Quintin
LHLusine Hovhannisyan
Lusine Hovhannisyan
MMMatúš Medo
Matúš Medo
MMMichaela Medova
Michaela Medova
Major risk factors of head and neck squamous cell carcinoma (HNSCC) are tobacco use and human papillomavirus (HPV). HPV E6 oncoprotein leads to p53 degradation, whereas HPV-negative cancers are frequently associated with TP53 mutations. Peposertib is a potent and selective, orally administered small-molecule inhibitor of the catalytic subunit of the DNA-dependent kinase (DNA-PKcs), a key regulator of nonhomologous end joining (NHEJ). NHEJ inhibition along with irradiation (IR)-induced DNA double-strand breaks has the potential to increase antitumor treatment efficacy. In this study, we investigated the responses of a panel of HNSCC models with distinct HPV and p53 status to treatments with IR, DNA-PKcs inhibition, and their combination in vitro and in vivo. IR-induced DNA damage combined with peposertib administration shortly before IR results in decreased cell viability and proliferation and causes DNA repair delay in all studied HNSCC cell lines. However, our data confirm that the actual cell fate upon this treatment is determined by cellular p53 and/or HPV status. Cells lacking functional p53 due to its degradation by HPV or due to a loss-of-function mutation are arrested in the G2/M phase of the cell cycle and eliminated by apoptosis, whereas p53-proficient HNSCC cell lines preferentially undergo senescence. This is also recapitulated in vivo, where HPV+ UD-SCC-2 xenografts display stronger and more durable responses to the combined treatment as compared with p53 wild-type UM-SCC-74A tumors. In conclusion, DNA-PKcs inhibitor peposertib should be further studied as a potential radiosensitizer for HNSCCs, taking into consideration the genetic background and the HPV status of a particular tumor.

6 September 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
RERoberta Esposito
Roberta Esposito
ALAndrés Lanzós
Andrés Lanzós
TUTina Uroda
Tina Uroda
SRSunandini Ramnarayanan
Sunandini Ramnarayanan
IBIsabel Büchi
Isabel Büchi
Rory JohnsonRory Johnson
Rory Johnson

4 November 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
LHLiana Hayrapetyan
Liana Hayrapetyan
SRSelina M. Roth
Selina M. Roth
LHLusine Hovhannisyan
Lusine Hovhannisyan
MMMatúš Medo
Matúš Medo
AQAurélie Quintin
Aurélie Quintin
MMMichaela Medova
Michaela Medova
Major risk factors of head and neck squamous cell carcinoma (HNSCC) are tobacco use and human papillomavirus (HPV). HPV E6 oncoprotein leads to the degradation of the p53 protein, whereas HPV-negative cancers are frequently associated with TP53 mutations. Peposertib is a potent and selective, orally administered small-molecule inhibitor of the catalytic subunit of the DNA-dependent kinase (DNA-PKcs), a key regulator of non-homologous end joining (NHEJ). NHEJ inhibition along with irradiation (IR)-induced DNA double-strand breaks has the potential to increase antitumor treatment efficacy. Here, we investigated the responses of HNSCC models with distinct HPV and p53 status to treatments with IR, DNA-PKcs inhibition, and their combination. We observed that IR-induced DNA damage combined with peposertib administration shortly before IR results in decreased cell viability and proliferation and causes DNA repair delay in all the studied HNSCC cell lines. However, our data confirm that the actual cell fate upon this treatment is strongly dependent on cellular p53/HPV status. Cells lacking functional p53 due to its degradation by HPV or due to the presence of a loss-of-function mutation are arrested in the G2 phase of the cell cycle and eliminated by apoptosis whereas p53-proficient HNSCC cell lines undergo senescence. Consequently, HPV+ cancer cell lines and xenografts display stronger and more durable responses and seem to benefit from the combined treatment more than p53-proficient HNSCCs. In conclusion, DNA-PKcs inhibitor peposertib should be further studied as a potential radiosensitizer for HNSCCs, taking into consideration the genetic background and the HPV status of a particular tumor.

4 February 2025
Verified
Other
Open access
PDF file
LHLiana Hayrapetyan
Liana Hayrapetyan
SRSelina M. Roth
Selina M. Roth
AQAurélie Quintin
Aurélie Quintin
LHLusine Hovhannisyan
Lusine Hovhannisyan
MMMatúš Medo
Matúš Medo
MMMichaela Medova
Michaela Medova
Cell cycle distribution and colony-forming assays: (A-C) Cell cycle distribution data at 7 hours (A), 24 hours (B), and 36 hours (C) after treatment (p values are not shown). (D) Colony-forming assay (two-way ANOVA with post hoc multiple comparisons. Data is represented as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).